Promising alternative strategies, such as repurposing drugs, have been considered for Parkinson’s Disease (PD). Within this framework, N-acetylcysteine (NAC) has shown promising results in preserving the dopaminergic system. Indeed, published data from our group revealed that NAC single-dose administration enhanced DAn viability, as we found that it could restore dopamine transporter (DAT) levels. With this in mind, we consider that NAC application could be a remarkable asset to approach PD. Therefore, in the present study, we addressed the impact of a 7-day treatment with NAC in a 6-hydroxydopamine (6-OHDA) intrastriatal animal model of PD.An in-house 6-OHDA rat model was used, mimicking PD symptomatology. Five weeks after lesion, NAC (1200mg/kg) was administered by oral gavage for seven consecutive days. Motor and non-motor behavior were analyzed to address the therapeutic relevance (of NAC) on functional outcomes. Furthermore, treatment impact on different areas/circuitries of the PD brain was also assessed.Preliminary in vivo studies revealed promising findings. From the results, we observed that NAC treatment significantly affected specific behavioral tests. Still, tissue evaluation revealed NAC's ability to modulate distinct mechanisms associated with PD degeneration and modifications in histological and molecular-cellular features.With the results acquired in this study, we provided an important proof-of-concept milestone regarding NAC therapeutical application. However, it is imperative to understand the complex capacity of NAC and how its therapeutic neuroprotective effects interact with cellular and molecular PD mechanisms. Doing so could open new avenues with significant gains in PD therapeutics and potential translation into clinics.